Investors seeking opportunities in the healthcare sector should pay attention to GH Research PLC (NASDAQ: GHRS), a promising player in the biotechnology industry. Based in Dublin, Ireland, GH Research is making waves with its innovative approach to treating depression, focusing on developing groundbreaking therapies for treatment-resistant depression and other psychiatric disorders.

GH Research’s lead product, GH001, is a pioneering inhalable mebufotenin candidate currently undergoing phase 2b clinical trials. This treatment targets patients with treatment-resistant depression and shows promising potential in addressing bipolar II disorder and postpartum depression. Additionally, GH002, an intravenous mebufotenin product, is in…